Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

essure alone and in combination with an ACE-I[5][6]. Further details about this proof-of-concept Phase II trial will be announced later in 2007 when it commences. The trial will be carried out in Europe with results due in the second half of 2008.

Speedel's next generation renin inhibitors include other compounds in the SPP600 series, the SPP1100 series with SPP1148 due to report first Phase I results in Q42007, and the SPP800 series currently in late-stage pre-clinical profiling. Each series is a different chemical class with distinct properties and is protected by different patent applications.


About SPP600 series
SPP635 is the most advanced compound of the SPP600 series of renin inhibitors being developed by Speedel. The company has made significant progress in the optimisation and development of this series of newly synthesised compounds by using rational drug design, including computer assisted molecular modelling techniques, state-of-the art preclinical disease models and human microdosing.

In December 2001, Speedel acquired a worldwide exclusive license from Roche covering its entire programme in renin inhibition. This license allows Speedel to use the acquired know-how for lead optimisation of its own compounds designated as the SPP600 series. Speedel holds full development and commercialization rights for these product candidates under the license agreement with Roche. If Speedel decides to offer rights to any Speedel compound from the series to a third party, Roche has a right of first negotiation with respect to such rights. If Roche has not expressed its interest in acquiring such rights within a defined period of time, or the parties have not reached an agreement on the terms of such rights, Speedel is free to grant such rights to any third party.

About Hypertension
Hypertension is a common disorder in which blood pressure is abnormally high, placing undue stress on the heart, b
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:9/18/2014)...   3D Systems   (NYSE: DDD ) ... , a new robotic surgery skills and procedural training simulator, ... ERUS exhibition in Amsterdam, The Netherlands ... minimally invasive surgery represents a growing portion of overall surgical ... for robotic surgery has increased, and it is expected that ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker discovery ... US trial of its MiStat™ prostate cancer screening test, ... regulatory approval upon completion. Minomic,s proprietary MiStat™ ... presence of a proprietary biomarker known as the MIL-38 ... prostate cancer cells. Researchers at 11 ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... EATONTOWN, N.J. , Jan. 14 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, today reported preliminary unaudited revenue for the ... $24.6 million for the same period in 2008.  During ... revenue from sales of its new innovative products all currently in ...
... and NORTH BRUNSWICK, N.J. , Jan. 14 ... that they have achieved the initial milestone of a research ... vitro test for potential allergic reactions to substances that could ... "Allergy Test on a Chip™," is intended to comprise a ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 2L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 3
(Date:9/18/2014)... September 18, 2014 Companies in the ... carbon dioxide, selling it to downstream industries in either ... carbon dioxide are food and beverage manufacturers. Food producers ... fruits, vegetables or pizzas. The gas is also used ... the compound to carbonate soft drinks, beer and other ...
(Date:9/18/2014)... supplements of selenium or vitamin E don,t seem ... men, a new study indicates. Previous animal research ... cataracts. To investigate this further, William Christen, from Brigham ... and his colleagues examined data from a randomized, placebo-controlled ... initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Stealth ... and wellness advocate, and Frank Davis, founder of ... Whole-food Nutrition, are pleased to announce the new ... to make delicious, nutrition-packed meals using Activz whole-food ... the next step in the Stealth Health ...
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3
... director of chemical and food safety programs with Pew Health ... response to the introduction of the Food Safety Modernization Act ... , "In the midst of an ongoing peanut product recall, ... not be more timely. The FSMA contains key improvements that ...
... The Greater Baltimore Committee is seeking nominations for ... Thursday, March 12, 2009. Those interested in nominating a ... . The four award categories are: Entrepreneurial, Best New ... Nominators will be asked to submit documentation and narratives ...
... Feb. 4 Speaker Nancy Pelosi and parents and children ... a photo opportunity this morning before the final House vote ... this afternoon. Below are the Speaker,s remarks and answer to ... in the House of Representatives and in the Congress of ...
... architect of BurrellesLuce 2.0, will be the featured speaker at the ... of America. , ... Livingston, NJ (PRWEB) February 4, 2009 -- Jeffrey ... , will be the featured speaker at the Feb. 11th luncheon ...
... Compuware Corporation (Nasdaq:, CPWR ) today announced ... Health,Initiative with a collaborative network for the secure ... The VIP Health,Initiative was formed by Scripps Mercy ... to enhance the quality of care,delivered while also ...
... Saturday, February 7 -- 8 a.m. - 3 p.m.DETROIT, Feb. ... more to smile about.With the help of dentists, dental hygienists, ... School of Dentistry will provide free oral health care ... Saturday, Feb. 7 from 8 a.m. to 3 p.m. on ...
Cached Medicine News:Health News:Statement From Pew Health & Human Services Policy Program on the Introduction of the Delauro Food Safety Modernization Act 2Health News:GBC Seeks Nominations for Fourth Annual Bioscience Awards 2Health News:Pelosi: 'Today is a Very Special Day for Us in the House; We Are Going to Help 11 Million Children' 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 2Health News:BurrellesLuce IT Expert to Explore Web 3.0's Potential PR Impact At February Luncheon Meeting of Westchester/Fairfield PRSA 3Health News:Compuware Covisint to Network VIP Health Initiative and Its Physicians, Enabling Improved Collaboration, Better Care 2Health News:Compuware Covisint to Network VIP Health Initiative and Its Physicians, Enabling Improved Collaboration, Better Care 3Health News:UDM School of Dentistry 'Gives Kids A Smile' 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: